Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative testosterone replacement after radical prostatectomy
NL-OMON60808Phase 3Completed
- Sponsor
- Canisius-Wilhelmina Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Hypogonadism and prostate cancer (PCa) comparing Testosterone replacement therapy with Placebo (2 arms). Primary endpoint: EPIC-26 sexual functioning domain score at 12 months. Started Dec 2022; status: completed.
02
Drugs
testosterone
03
Conditions
Hypogonadismprostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON60808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60808.